Clinical trials: Nonradiographic Axial Spondyloarthritis
Nonradiographic Axial Spondylitis, Ankylosing
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy and safety of ustekinumab in adult participants with active nonradiographic axial spondyloarthritis (nr-AxSpA) measured by the reduction in signs and symptoms of nonradiographic…
- Trial name
- NCT02407223
- Testing
- Group 2: Ustekinumab 45 mg, Group 3: Ustekinumab 90 mg
- Where
- 90 sites in Argentina, Australia and 12 more
- Volunteers
- 356 people
- Sponsor
- Janssen Research & Development, LLC
Axial Spondyloarthritis
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis…
- Trial name
- COAST-X (NCT02757352)
- Testing
- Ixekizumab
- Where
- 109 sites in United States, Argentina and 14 more
- Volunteers
- 303 people
- Sponsor
- Eli Lilly and Company
Nonradiographic Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis…
- Trial name
- BE MOBILE 1 (NCT03928704)
- Testing
- Bimekizumab
- Where
- 83 sites in United States, Belgium and 11 more
- Volunteers
- 274 people
- Sponsor
- UCB Biopharma SRL
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Trial name
- C-AXSPAND (NCT02552212)
- Testing
- Certolizumab Pegol
- Where
- 105 sites in United States, Australia and 7 more
- Volunteers
- 317 people
- Sponsor
- UCB BIOSCIENCES GmbH